Alpha Cognition Inc. (NASDAQ: ACOG) Q2 2025 Earnings Call | 08/15/2025
AI Summary
Alpha Cognition Inc. reported its Q2 2025 financial results, marking its first earnings call following the commercial launch of Zunval, a treatment for mild to moderate Alzheimer’s disease. The call highlighted commercial progress, financial performance, research and development updates, and business development milestones.
Key Highlights
- Commercial Launch of Zunval
- Market Penetration: The sales team engaged over 3,700 healthcare providers (HCPs) in the long-term care (LTC) market, with prescriptions written in over 300 nursing homes. 65% of these facilities had repeat prescriptions, indicating strong product trial.
- Prescriber Engagement: 1,564 unique prescribers were reached, with 370 writing at least one Zunval prescription, and 56% writing multiple prescriptions.
- Payer Progress: A contract was signed with a major national health plan, providing access to ~17 million Medicare Part D lives. Additional payer discussions are ongoing, with expectations of at least one more large contract by year-end.
- Challenges: Increased demand led to more prior authorizations, delaying fulfillment (up to three weeks), though 90% of orders were filled.
- Behavioral Messaging: New messaging emphasizing Zunval’s benefits on behavioral symptoms (aligned with the Neuropsychiatric Inventory) has broadened its appeal, targeting patients with or without prior cholinesterase inhibitor use.
- Financial Performance
- Revenue: $1.7 million in total revenue, including $1.6 million from Zunval sales and $81,000 from licensing with CMS Pharmaceuticals. Total Zunval net revenue since launch: ~$2 million.
- Expenses: Operating expenses were $6.9 million (up from $2.4 million in Q2 2024), driven by Zunval’s commercial launch. Total costs and expenses: $7.4 million.
- Net Loss: $10.5 million ($0.65/share), compared to $2.1 million ($0.35/share) in Q2 2024, primarily due to a $5.2 million non-cash loss from warrant liabilities.
- Cash Position: $39.4 million in unrestricted cash and cash equivalents as of June 30, 2025, plus $425,000 in interest income.
- Guidance: Full-year 2025 operating expenses projected at $34–38 million, reflecting cost optimization and efficient resource allocation.
- Research and Development
- Sublingual Formulation: Development for Alzheimer’s patients with dysphagia/aphasia (20% of patients) is on track, with formulation and tasting work expected to conclude in Q1 2026. A comparative PK study and IND submission are planned for H1 2026.
- TBI Study: A preclinical study with Alpha-1062 (funded by a Department of Defense grant) showed reduced neuroinflammation, neuropathology, and toxic Tau protein levels in a bomb blast model, suggesting potential for traumatic brain injury (TBI) treatment.
- Business Development
- Partnered with CMS Pharmaceuticals for Zunval in China and Greater Asia. Chinese regulatory authorities accepted Zunval’s application for review, with filings planned in four additional countries by year-end. Ex-US revenues are expected in late 2026.
- Outlook
- Commercial Focus: Expand Zunval’s presence in LTC homes, increase repeat prescribers, deepen HCP engagement, and advance payer access for 2026.
- Financial Discipline: Maintain cost efficiency while scaling commercial efforts.
- Revenue Expectations: Monthly net revenue run rate for Q3 2025 projected at $575,000–$625,000. A $3 million tranche from CMS is expected in Q4 2025.
- Long-Term Growth: Anticipates a “hockey stick” revenue curve, with significant ex-US revenue contributions in late 2026/early 2027.
Q&A Highlights
- Repeat Prescribers (Ram Salvaraju): No specific profile for repeat prescribers, as the focus is on high-volume LTC facilities with Alzheimer’s patients. Consistent messaging and frequent visits drive repeat prescriptions.
- Prior Authorizations (Ram Salvaraju): Increased demand led to more prior authorizations, requiring evidence of prior generic use or intolerance. Approval rates remain high (90%), but delays persist.
- Capital Allocation (Ram Salvaraju): R&D costs for sublingual formulation and TBI programs are included in the $34–38 million expense guidance, with low-cost formulation work ongoing.
- Patient Types (Boris Peeker): Zunval is used for patients switching from donepezil, those previously intolerant to treatments, and increasingly for behavioral symptom management.
- Net Discount (Boris Peeker): Current net discount is ~$600, expected to stabilize at $575–$625 over the next few quarters.
- Revenue Curve (Dave Storms): No change to the expected “hockey stick” revenue trajectory, with steady growth in LTC and significant ex-US contributions in 2026–2027.
- Operating Expenses (Dave Storms): Expected to stabilize at $34–38 million over the next 3–4 quarters.
About this video
Alpha Cognition Inc. reported its Q2 2025 financial results reflecting continued progress in its commercial launch and pipeline development. The company achieved $1.7 million in total revenue for the quarter, driven primarily by $1.6 million in net product sales of ZUNVEYL, its lead commercial therapy for Alzheimer's disease. Licensing revenue contributed an additional $81,000. Research and development expenses declined to $317,000, a significant decrease compared to the prior year, while selling, general, and administrative expenses rose to $6.5 million due to investments in commercial readiness and expansion activities. The net operating loss increased to $5.7 million from $2.4 million a year prior, and the net loss widened to $10.5 million, mainly impacted by a $5.2 million non-cash loss related to warrant liabilities. Operational highlights include robust clinician engagement, with the sales team interacting with over 3,700 healthcare professionals and generating prescriptions in more than 300 nursing homes. The company’s international partner, CMS Pharmaceuticals, has filed ZUNVEYL in four additional countries, targeting ex-U.S. revenue by late 2026. As of June 30, 2025, cash and cash equivalents stood at $39.4 million, supporting an estimated cash runway of approximately two years. About Inside Ticker: Inside Ticker delivers precise, professional earnings coverage and insightful market analysis for investors and industry professionals. Visit us at https://www.insideticker.com/ #AlphaCognition #ACOG #Q22025 #Earnings #FinancialResults #Revenue #NetLoss #ZUNVEYL #Alzheimers #Biopharma #CommercialLaunch #ClinicalData #HealthcareInnovation #R&D #Investment #StockMarket #EarningsCall #MarketUpdate #Biotechnology #Healthcare
Video Stats
More from this category

Dell Technologies Inc. (NYSE: DELL) Q1 2026 Earnings Call | AI Server Demand | 5/30/2025
Inside Ticker

Mama's Creations, Inc. (NASDAQ: MAMA) Q1 2026 Earnings Call | 6/3/2025
Inside Ticker

Sportsman’s Warehouse Holdings, Inc. (NASDAQ: SPWH) Q1 2025 Earnings Call | 6/3/2025
Inside Ticker

Hewlett Packard Enterprise Company (NYSE: HPE) Q2 2025 Earnings Call | 6/3/2025
Inside Ticker

Yext, Inc. (NYSE: YEXT) Q1 2026 Earnings Call | 6/3/2025
Inside Ticker

Elastic N.V. (NYSE: ESTC) Q4 2025 Earnings Call | Cloud Revenue Surges & AI Platform | 5/30/2025
Inside Ticker

CrowdStrike Holdings, Inc. (NASDAQ: CRWD) Q1 2026 Earnings Call | 6/3/2025
Inside Ticker

Zscaler (ZS) Q3 2025 Earnings Call | Revenue Beats & AI Security Highlights | May 2025
Inside Ticker

BARK, Inc. (NYSE: BARK) Q4 2025 Earnings Call | 6/4/2025
Inside Ticker

lululemon athletica inc. (NASDAQ: LULU) Q1 2025 Earnings Call | 6/5/2025
Inside Ticker

Sprinklr, Inc. (NYSE: CXM) Q1 2026 Earnings Call | 6/4/2025
Inside Ticker

Braze, Inc. (NASDAQ: BRZE) Q1 2026 Earnings Call | 6/5/2025
Inside Ticker
